In patients with rheumatoid arthritis, the administration of n-3 PUFAs for 6 months significantly reduced levels of TNF-α, IL-1β, and prostaglandin E2 from the baseline and increased levels of the anti-inflammatory cytokine IL-10 [23]. This evidence concerns the gene IL1B and rheumatoid arthritis.